Literature DB >> 21498342

Central venous device-related thrombosis as imaged with MDCT in oncologic patients: prevalence and findings.

Orlando Catalano1, Elisabetta de Lutio di Castelguidone, Claudia Sandomenico, Mario Petrillo, Pasquale Aprea, Vincenza Granata, Adolfo Gallipoli D'Errico.   

Abstract

BACKGROUND: Venous thrombosis is a common occurrence in cancer patients, developing spontaneously or in combination with indwelling central venous devices (CVD).
PURPOSE: To analyze the multidetector CT (MDCT) prevalence, appearance, and significance of catheter-related thoracic venous thrombosis in oncologic patients and to determine the percentage of thrombi identified in the original reports.
MATERIAL AND METHODS: Five hundred consecutive patients were considered. Inclusion criteria were: presence of a CVD; availability of a contrast-enhanced MDCT; and cancer history. Exclusion criteria were: direct tumor compression/infiltration of the veins; poor image quality; device tip not in the scanned volume; and missing clinical data. Seventeen (3.5%) out of the final 481 patients had a diagnosis of venous thrombosis.
RESULTS: Factors showing the highest correlation with thrombosis included peripherally-inserted CVD, right brachiocephalic vein tip location, patient performance status 3, metastatic stage disease, ongoing chemotherapy, and longstanding CVD. The highest prevalence was in patients with lymphoma, lung carcinoma, melanoma, and gynecologic malignancies. Eleven out of 17 cases had not been identified in the original report.
CONCLUSION: CVD-related thrombosis is not uncommon in cancer patients and can also be observed in outpatients with a good performance status and a non-metastatic disease. Thrombi can be very tiny. Radiologists should be aware of the possibility to identify (or overlook) small thrombi.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498342     DOI: 10.1258/ar.2010.100294

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients.

Authors:  Shoutian Lv; Yongmei Liu; Gang Wei; Xueyan Shi; Shaoping Chen; Xuehui Zhang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.889

2.  Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis.

Authors:  Yajuan Lv; Yong Hou; Bo Pan; Yuwan Ma; Paiyun Li; Lili Yu; Deguo Xu; Juanjuan Song; Heli Shang; Hongyan Wang; Yuan Tian
Journal:  Oncotarget       Date:  2018-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.